Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
06/07/2023 | Jasper Therapeutics, Inc. | AMHCU | Grant | Stock Option (right to buy) | 47k | $1.60 | $75.2k | | 06/07/2023 |
01/25/2023 | CymaBay Therapeutics, Inc. | CBAY | Grant | Stock Option (right to buy) | 25k | $7.80 | $195k | | 01/25/2023 |
10/12/2022 | Jasper Therapeutics, Inc. | AMHCU | Grant | Voting Common Stock | 30.2k | $0.00 | $0 | | 10/12/2022 |
03/21/2022 | Jasper Therapeutics, Inc. | AMHCU | Grant | Stock Option (right to buy) | 78k | $3.54 | $276.3k | | 03/21/2022 |
01/25/2022 | CymaBay Therapeutics, Inc. | CBAY | Grant | Stock Option (right to buy) | 67k | $2.94 | $197k | | 01/25/2022 |
06/02/2021 | Vaxcyte, Inc. | PCVX | Grant | Stock option (right to buy) | 15k | $21.49 | $322.4k | | 06/02/2021 |
05/18/2021 | Vera Therapeutics, Inc. | | Conversion | Class A Common Stock | 2.2M | $0.00 | $0 | See footnote | 05/17/2021 |
05/18/2021 | Vera Therapeutics, Inc. | | Purchase | Class A Common Stock | 772.7k | $11.00 | $8.5M | See footnote | 05/17/2021 |
05/18/2021 | Vera Therapeutics, Inc. | | Conversion | Series C Preferred Stock | 2.2M | $0.00 | $0 | See footnote | 05/17/2021 |
05/17/2021 | Vera Therapeutics, Inc. | | Purchase | Class A Common Stock | 17.8k | $12.04 | $214.7k | | 05/17/2021 |
05/13/2021 | Vera Therapeutics, Inc. | | Grant | Stock Option (right to buy) | 9.9k | $11.00 | $109.2k | | 05/13/2021 |
01/26/2021 | CymaBay Therapeutics, Inc. | CBAY | Grant | Stock Option (right to buy) | 32k | $5.78 | $185k | | 01/26/2021 |
06/16/2020 | Vaxcyte, Inc. | PCVX | Conversion | Common Stock, $0.001 par value per share | 2.2M | $0.00 | $0 | See Footnotes | 06/16/2020 |
06/16/2020 | Vaxcyte, Inc. | PCVX | Conversion | Common Stock, $0.001 par value per share | 1.2M | $0.00 | $0 | See Footnotes | 06/16/2020 |
06/16/2020 | Vaxcyte, Inc. | PCVX | Conversion | Common Stock, $0.001 par value per share | 454.8k | $0.00 | $0 | See Footnotes | 06/16/2020 |
06/16/2020 | Vaxcyte, Inc. | PCVX | Conversion | Common Stock, $0.001 par value per share | 298.9k | $0.00 | $0 | See Footnotes | 06/16/2020 |
06/16/2020 | Vaxcyte, Inc. | PCVX | Purchase | Common Stock, $0.001 par value per share | 12.5k | $16.00 | $200k | See Footnotes | 06/16/2020 |
06/16/2020 | Vaxcyte, Inc. | PCVX | Conversion | Series A Preferred Stock | 2.2M | $0.00 | $0 | See Footnotes | 06/16/2020 |
06/16/2020 | Vaxcyte, Inc. | PCVX | Conversion | Series B Preferred Stock | 1.2M | $0.00 | $0 | See Footnotes | 06/16/2020 |
06/16/2020 | Vaxcyte, Inc. | PCVX | Conversion | Series C Preferred Stock | 454.8k | $0.00 | $0 | See Footnotes | 06/16/2020 |
06/16/2020 | Vaxcyte, Inc. | PCVX | Conversion | Series D Preferred Stock | 298.9k | $0.00 | $0 | See Footnotes | 06/16/2020 |
06/11/2020 | Vaxcyte, Inc. | PCVX | Grant | Stock option (right to buy) | 40k | $16.00 | $640k | | 06/11/2020 |
06/11/2020 | Vaxcyte, Inc. | PCVX | Grant | Stock option (right to buy) | 40k | $16.00 | $640k | | 06/11/2020 |
05/15/2020 | CymaBay Therapeutics, Inc. | CBAY | Grant | Stock Option (Right to Buy) | 49.2k | $4.05 | $199.4k | | 05/15/2020 |
01/29/2019 | CymaBay Therapeutics, Inc. | CBAY | Grant | Stock option (right to buy) | 27.7k | $8.43 | $233.6k | | 01/29/2019 |
12/18/2018 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 62.9k | $29.70 | $1.9M | See Footnote | 12/18/2018 |
12/18/2018 | CymaBay Therapeutics, Inc. | CBAY | Sale | Common Stock | 53.5k | $7.43 | $397.4k | See footnotes | 12/17/2018 |
12/18/2018 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 69.9k | $29.70 | $2.1M | See Footnote | 12/17/2018 |
12/17/2018 | CRISPR Therapeutics AG | CRSP | Sale | Common Shares | 3k | $33.17 | $99.8k | See Footnote | 12/17/2018 |
12/17/2018 | CymaBay Therapeutics, Inc. | CBAY | Sale | Common Stock | 88.9k | $8.17 | $726.2k | See footnotes | 12/17/2018 |
06/15/2018 | CRISPR Therapeutics AG | CRSP | Grant | Stock Option (Right to Buy) | 15k | $59.31 | $889.6k | | 06/15/2018 |
06/05/2018 | CymaBay Therapeutics, Inc. | CBAY | Sale | Common Stock | 920 | $12.51 | $11.5k | By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 | 06/05/2018 |
06/05/2018 | CymaBay Therapeutics, Inc. | CBAY | Exercise (in-the-money or at-the-money) | Warrant (right to buy) | 2k | $5.75 | $11.5k | By The Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 | 06/05/2018 |
06/05/2018 | CRISPR Therapeutics AG | CRSP | Sale | Common Stock | 920 | $12.51 | $11.5k | By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 | 06/05/2018 |
06/05/2018 | CRISPR Therapeutics AG | CRSP | Exercise (in-the-money or at-the-money) | Warrant (right to buy) | 2k | $5.75 | $11.5k | By The Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 | 06/05/2018 |
|